Tekla Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Tekla Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$12.7M	Buy	58,577 +5,125	+10%	+$1.1M	0.5%	47
2023 Q1	$9.71M	Hold	53,452	–	–	0.37%	57
2022 Q4	$10.5M	Buy	53,452 +29,836	+126%	+$6.4M	0.4%	56
2022 Q3	$5.31M	Sell	23,616 -55,441	-70%	-$11.2M	0.22%	74
2022 Q2	$10M	Sell	79,057 -21,401	-21%	-$2.46M	0.39%	61
2022 Q1	$12.7M	Hold	100,458	–	–	0.45%	54
2021 Q4	$13.2M	Hold	100,458	–	–	0.42%	55
2021 Q3	$12.3M	Hold	100,458	–	–	0.4%	61
2021 Q2	$11.5M	Buy	100,458 +15,222	+18%	+$1.78M	0.37%	72
2021 Q1	$10.2M	Hold	85,236	–	–	0.35%	73
2020 Q4	$8.66M	Buy	85,236 +43,409	+104%	+$4.02M	0.3%	91
2020 Q3	$3.23M	Buy	41,827 +11,954	+40%	+$1.02M	0.12%	123
2020 Q2	$3.33M	Buy	+29,873	New	+$2.6M	0.13%	130

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tekla Capital Management's KRTX Position: Q2 2023 in Review

Tekla Capital Management increased its Karuna Therapeutics, Inc. Common Stock (KRTX) stake by 9.6% in Q2 2023, buying an estimated $1.1M and bringing the position to 58,577 shares worth $12.7M. The position accounts for 0.5% of the portfolio, ranked #47.

Tekla Capital Management first reported a position in KRTX in Q2 2020 and has held it in 13 quarters since. The position peaked at $13.2M in Q4 2021. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

Tekla Capital Management held 58,577 shares of Karuna Therapeutics, Inc. Common Stock worth $12.7M as of Q2 2023.
Tekla Capital Management bought 5,125 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.1M.
Karuna Therapeutics, Inc. Common Stock made up 0.5% of Tekla Capital Management's portfolio in Q2 2023, its #47 holding.
Tekla Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and has held it in 13 quarters since.
Tekla Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $13.2M in Q4 2021.
289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.